A protein subunit therapeutic cancer vaccine that delivers tumor antigens to antigen-presenting cells to prime adaptive antitumor immunity.
Self-adjuvanted chimeric protein subunit cancer vaccine that targets and penetrates dendritic cells via a CPP, delivers multiple MHC I/II–restricted tumor antigen peptides with an embedded TLR agonist, leading to antigen processing and presentation, activation of CD8+ and CD4+ T cells, and induction of adaptive antitumor immunity against pancreatic cancer cells.
NO
INDIRECT
The vaccine is taken up by HLA‑DQ+ antigen‑presenting cells, which present peptides to activate CD4+ and CD8+ T cells; the resulting CTLs kill antigen-expressing tumor cells, not the HLA‑DQ–expressing APCs.
A protein subunit therapeutic cancer vaccine designed to present tumor antigens to dendritic cells/APCs to prime tumor-specific T-cell responses.
Self-adjuvanted chimeric protein vaccine (KISIMA platform) that uses a cell-penetrating peptide to deliver multiple tumor-associated antigen peptides into dendritic cells and a TLR peptide agonist to activate them; promotes processing and presentation on MHC I and II to prime tumor-specific CD8+ and CD4+ T cells, inducing cytotoxic anti-tumor immunity in pancreatic cancer.
NO
INDIRECT
TLR agonism activates dendritic cells and delivers antigen for presentation, priming cytotoxic CD8+ T cells that kill tumor cells; TLR-expressing APCs are not directly killed.
A protein subunit therapeutic cancer vaccine designed to present tumor antigens to dendritic cells/APCs to prime tumor-specific T-cell responses.
Self-adjuvanted chimeric protein vaccine (KISIMA platform) that uses a cell-penetrating peptide to deliver multiple tumor-associated antigen peptides into dendritic cells and a TLR peptide agonist to activate them; promotes processing and presentation on MHC I and II to prime tumor-specific CD8+ and CD4+ T cells, inducing cytotoxic anti-tumor immunity in pancreatic cancer.
NO
INDIRECT
The vaccine primes tumor-specific CD8+ T cells via dendritic cell presentation; activated T cells then kill tumor cells presenting vaccine-derived peptides on HLA-A through TCR recognition and perforin/granzyme-mediated cytolysis. HLA-A itself is not the direct cytotoxic target.
A protein subunit therapeutic cancer vaccine designed to present tumor antigens to dendritic cells/APCs to prime tumor-specific T-cell responses.
Self-adjuvanted chimeric protein vaccine (KISIMA platform) that uses a cell-penetrating peptide to deliver multiple tumor-associated antigen peptides into dendritic cells and a TLR peptide agonist to activate them; promotes processing and presentation on MHC I and II to prime tumor-specific CD8+ and CD4+ T cells, inducing cytotoxic anti-tumor immunity in pancreatic cancer.
NO
INDIRECT
The vaccine primes tumor-specific CD8+ T cells via dendritic cell antigen presentation; CTLs then kill tumor cells presenting vaccine-encoded peptides on MHC I (e.g., HLA-B) via perforin/granzyme apoptosis. HLA-B itself is not the cytotoxic target.
A protein subunit therapeutic cancer vaccine designed to present tumor antigens to dendritic cells/APCs to prime tumor-specific T-cell responses.
Self-adjuvanted chimeric protein vaccine (KISIMA platform) that uses a cell-penetrating peptide to deliver multiple tumor-associated antigen peptides into dendritic cells and a TLR peptide agonist to activate them; promotes processing and presentation on MHC I and II to prime tumor-specific CD8+ and CD4+ T cells, inducing cytotoxic anti-tumor immunity in pancreatic cancer.
NO
INDIRECT
Vaccine delivers tumor peptides to dendritic cells, priming CD8+ T cells that kill tumor cells presenting those peptides on MHC I. HLA-C itself is not the target; cells expressing HLA-C alone are not directly killed.